Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Autologous haematopoietic… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: The Swedish experience

Artikel i vetenskaplig tidskrift
Författare Joachim Burman
Ellen Iacobaeus
Anders Svenningsson
Jan Lycke
Martin Gunnarsson
Petra Nilsson
Magnus Vrethem
Sten Fredrikson
Claes Martin
Anna Sandstedt
Bertil Uggla
Stig Lenhoff
Jan-Erik Johansson
Cecilia Isaksson
Hans Hägglund
Kristina Carlson
Jan Fagius
Publicerad i Journal of Neurology, Neurosurgery and Psychiatry
Volym 85
Sidor 1116-1121
ISSN 00223050
Publiceringsår 2014
Publicerad vid
Sidor 1116-1121
Språk en
Ämneskategorier Neurovetenskaper

Sammanfattning

Background: Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS. Methods: Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months. Results: At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and diseasefree survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%). Conclusions: HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?